Overview article (in German) about apceth Biopharma published in Transkript 3/19. Advertorial apceth in tk 3-2019

Alpha-1 Antitrypsin-Expressing Mesenchymal Stromal Cells Confer a Long-Term Survival Benefit in a Mouse Model of Lethal GvHD Authors: Sabine Geiger,1,5 Emrah I. Ozay,2,3,5 Ulf Geumann,1,5 Marina K. Hereth,1 Terese Magnusson,1 Sudarvili Shanthalingam,3 Daniela Hirsch,1 Stefanie Kälin,1 Christine Günther,1 Barbara A. Osborne,2,3 Gregory N. Tew,4 Felix G. Hermann,1,6 and Lisa M. Minter2,3,6 1apceth Biopharma GmbH, 81377 Munich, Germany; 2Program in Molecular & Cellular Biology, University of Massachusetts Amherst, Amherst, MA 01003, USA; 3Department of Veterinary and Animal Sciences, University of Massachusetts Amherst, Amherst, MA 01003, USA; 4Department of Polymer Science and Engineering, University of Massachusetts Amherst, Amherst, MA 01003, USA Molecular Therapy Published: May 15, 2019 DOI: https://doi.org/10.1016/j.ymthe.2019.05.007 Please note: today apceth Biopharma focuses solely on the CDMO business

Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT‐ME‐1 trial Authors: Jobst Christian von Einem, Christine Guenther, Hans‐Dieter Volk, Gerald Grütz, Daniela Hirsch, Christoph Salat, Oliver Stoetzer, Peter J. Nelson, Marlies Michl, Dominik P. Modest, Julian W. Holch, Martin Angele, Christiane Bruns, Hanno Niess, Volker Heinemann International Journal of Cancer, first published 23 February 2019 https://doi.org/10.1002/ijc.32230 Please note: today apceth Biopharma focuses solely on the CDMO business  

Human Stem Cells Promote Liver Regeneration After Partial Hepatectomy in BALB/C Nude Mice Simon Wabitsch, MD,a,* Christian Benzing, MD,a Felix Krenzien, MD,a Katrin Splith, PhD,a Philipp Konstantin Haber, MD,a Alexander Arnold, MD,b Maximilian Nösser,a Can Kamali,a Felix Hermann, PhD,c Christine Günther, PhD,c Daniela Hirsch, PhD,c Igor M. Sauer, MD,a Johann Pratschke, MD,a and Moritz Schmelzle, MDa a Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité Universitätsmedizin, Berlin, Germany b Department of Pathology, Campus Charité Mitte and Campus Virchow-Klinikum, Charité Universitaetsmedizin, Berlin, Germany c Apceth Biopharma GmbH, Munich, Germany Journal of Surginal Research, July 2019,Volume 239, Pages 191–200 To the article: https://doi.org/10.1016/j.jss.2019.02.010 Please note: today apceth Biopharma focuses solely on the CDMO business

This phase I/II, first-in-class, first-in-men clinical trial tested safety, tolerability and efficacy of genetically modified mesenchymal stem cells (MSC) in the treatment of advanced, recurrent gastrointestinal cancer. Download publication: Publication_apceth Biopharma_TREAT-ME 1 clinical trial Please note: today apceth Biopharma focuses solely on the CDMO business

Geiger S, Hirsch D, Hermann FG. Cell therapy for lung disease Eur Respir Rev. 2017 Jun 28;26(144). Print 2017, Jun 30. Download Publication – Geiger 2017 (PDF) Please note: today apceth Biopharma focuses solely on the CDMO business

„Mesenchymal Stromal Cells Protect Endothelial Cells from Cytotoxic T Lymphocyte-Induced Lysis“

apceth, the global innovator and leader

Dr. Christine Günther, apceth CEO, elected as a member of vfa bio Executive Board

apceth experts published a book “Advances in Pharmaceutical Cell Therapy: Principles of Cell-Based Biopharmaceuticals”